Star Combo Pharma

Star Combo Pharma Equity

The The Equity of Star Combo Pharma (S66.AX) as of Nov 6, 2026 is 38.83 M AUD. In the previous year, The Equity was 38.08 M AUD — a change of 1.98% (higher).

Equity

38.83 MAUD

YoY

1.98%

Last updated:

In 2026, Star Combo Pharma's equity was 38.83 M AUD, a 1.98% increase from the 38.08 M AUD equity in the previous year.

The Star Combo Pharma Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
20.00 M AUD
Jan 1, 2020
44.50 M AUD
Jan 1, 2021
36.19 M AUD
Jan 1, 2022
35.41 M AUD
Jan 1, 2023
33.09 M AUD
Jan 1, 2024
33.32 M AUD
Jan 1, 2025
38.08 M AUD
Jan 1, 2026
38.83 M AUD
The Star Combo Pharma Equity history
YEAREquityYoY
38.83 MAUD+1.98%
38.08 MAUD+14.26%
33.32 MAUD+0.70%
33.09 MAUD-6.53%
35.41 MAUD-2.18%
36.19 MAUD-18.67%
44.50 MAUD+122.50%
20.00 MAUD+23.02%
16.26 MAUD+3.68%
15.68 MAUD+303.72%
3.88 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Star Combo Pharma Stock analysis

What does Star Combo Pharma do? Star Combo Pharma is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Star Combo Pharma's Equity

Star Combo Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Star Combo Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Star Combo Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Star Combo Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Star Combo Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Star Combo Pharma stock

The Equity of Star Combo Pharma is 38.83 M AUD in 2026.

The Equity of Star Combo Pharma changed from 38.08 M AUD to 38.83 M AUD, representing a 1.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Star Combo Pharma since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Star Combo Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Star Combo Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Star Combo Pharma